{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T13:52:13Z","timestamp":1771336333055,"version":"3.50.1"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T00:00:00Z","timestamp":1553212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Anlotinib is a tyrosine kinase inhibitor inhibiting angiogenesis. This multicenter, randomized phase II trial aimed to investigate the efficacy and safety of anlotinib in comparison with sunitinib as first-line treatment for patients with metastatic renal cell carcinoma (mRCC).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>Patients with mRCC from 13 clinical centers were randomly assigned in a 2:1 ratio to receive anlotinib (n =\u200990) or sunitinib (n =\u200943). Anlotinib was given orally at a dose of 12\u2009mg once daily (2\u2009weeks on\/1\u2009week off), and sunitinib was given orally at 50\u2009mg once daily (4\u2009weeks on\/2\u2009weeks off). The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), objective response rate (ORR), disease control rate (DCR), and safety.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The median PFS was similar with anlotinib and sunitinib (17.5 vs. 16.6\u2009months, p &amp;gt;\u2009.05). The median OS (30.9 vs. 30.5\u2009months, p &amp;gt;\u2009.05), ORR (30.3% vs. 27.9%), and 6-week DCR (97.8% vs. 93.0%) were similar in the two groups. Adverse events (AEs) of grade 3 or 4 were significantly less frequent with anlotinib than with sunitinib (28.9% vs. 55.8%, p &amp;lt;\u2009.01), especially in terms of thrombocytopenia and neutropenia. AEs occurring at a lower frequency with anlotinib were hand-foot syndrome, eyelid edema, hair depigmentation, skin yellowing, neutropenia, thrombocytopenia, and anemia. The incidence of serious AEs was lower with anlotinib than with sunitinib.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The clinical efficacy of anlotinib was similar to that of sunitinib as the first-line treatment for mRCC, but with a more favorable safety profile.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2018-0839","type":"journal-article","created":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T19:35:20Z","timestamp":1553283320000},"page":"e702-e708","source":"Crossref","is-referenced-by-count":80,"title":["Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial"],"prefix":"10.1093","volume":"24","author":[{"given":"Ai-Ping","family":"Zhou","sequence":"first","affiliation":[{"name":"National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxian","family":"Bai","sequence":"additional","affiliation":[{"name":"Harbin Medical University Affiliated Tumor Hospital, Harbin, Heilongjiang, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Song","sequence":"additional","affiliation":[{"name":"National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Luo","sequence":"additional","affiliation":[{"name":"Chongqing Cancer Hospital, Chongqing, Chongqing, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiu-Bao","family":"Ren","sequence":"additional","affiliation":[{"name":"Tianjin Medical University Cancer Institute and Hospital, Tianjin, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuwen","family":"Wang","sequence":"additional","affiliation":[{"name":"Qilu Hospital of Shandong University, Jinan, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benkang","family":"Shi","sequence":"additional","affiliation":[{"name":"Qilu Hospital of Shandong University, Jinan, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Fu","sequence":"additional","affiliation":[{"name":"Liaoning Province Tumor Hospital, Shenyang, Liaoning, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Cheng","sequence":"additional","affiliation":[{"name":"Jilin Cancer Hospital, Changchun, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiyan","family":"Liu","sequence":"additional","affiliation":[{"name":"West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shukui","family":"Qin","sequence":"additional","affiliation":[{"name":"The 81st Hospital of Chinese PLA, Nanjing, Jiangsu, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[{"name":"Gansu Province Cancer Hospital, Lanzhou, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanzhong","family":"Li","sequence":"additional","affiliation":[{"name":"Peking Union Medical College Hospital, Beijing, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianzhong","family":"Bai","sequence":"additional","affiliation":[{"name":"Guangxi Medical University Affiliated Tumor Hospital, Nanning, Guangxi, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dingwei","family":"Ye","sequence":"additional","affiliation":[{"name":"Cancer Hospital of Fudan University, Shanghai, Shanghai, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinwan","family":"Wang","sequence":"additional","affiliation":[{"name":"National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianhui","family":"Ma","sequence":"additional","affiliation":[{"name":"National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,3,22]]},"reference":[{"key":"2021122507442912700_R1","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/nrurol.2010.46","article-title":"Epidemiology and risk factors for kidney cancer","volume":"7","author":"Chow","year":"2010","journal-title":"Nat Rev Urol"},{"key":"2021122507442912700_R2","doi-asserted-by":"crossref","first-page":"17009","DOI":"10.1038\/nrdp.2017.9","article-title":"Renal cell carcinoma","volume":"3","author":"Hsieh","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"suppl 2","key":"2021122507442912700_R3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1634\/theoncologist.2011-S2-01","article-title":"New perspectives on the treatment of metastatic renal cell carcinoma: An introduction and historical overview","volume":"16","author":"Motzer","year":"2011","journal-title":"The Oncologist"},{"key":"2021122507442912700_R4","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ccell.2015.12.004","article-title":"An integrated metabolic atlas of clear cell renal cell carcinoma","volume":"29","author":"Hakimi","year":"2016","journal-title":"Cancer Cell"},{"key":"2021122507442912700_R5","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1158\/1078-0432.CCR-06-1989","article-title":"Vascular endothelial growth factor\u2013targeted therapy in renal cell carcinoma: Current status and future directions","volume":"13","author":"Rini","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2021122507442912700_R6","author":"Motzer","year":"2018"},{"issue":"suppl 5","key":"2021122507442912700_R7","doi-asserted-by":"crossref","first-page":"v58","DOI":"10.1093\/annonc\/mdw328","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Escudier","year":"2016","journal-title":"Ann Oncol"},{"key":"2021122507442912700_R8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12935-018-0530-2","article-title":"Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma","volume":"18","author":"Lai","year":"2018","journal-title":"Cancer Cell Int"},{"key":"2021122507442912700_R9","doi-asserted-by":"crossref","first-page":"e479","DOI":"10.1016\/j.clgc.2016.04.003","article-title":"Prescribing preferences in the first-line treatment for patients with metastatic renal cell carcinoma in the United States","volume":"14","author":"Hackshaw","year":"2016","journal-title":"Clin Genitourin Cancer"},{"key":"2021122507442912700_R10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1634\/theoncologist.2016-0197","article-title":"Sunitinib: Ten years of successful clinical use and study in advanced renal cell carcinoma","volume":"22","author":"Motzer","year":"2017","journal-title":"The Oncologist"},{"key":"2021122507442912700_R11","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1093\/jjco\/hyq146","article-title":"Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma","volume":"40","author":"Tomita","year":"2010","journal-title":"Jpn J Clin Oncol"},{"key":"2021122507442912700_R12","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13045-018-0617-1","article-title":"Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial","volume":"11","author":"Guo","year":"2018","journal-title":"J Hematol Oncol"},{"key":"2021122507442912700_R13","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1111\/cas.13536","article-title":"Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor","volume":"109","author":"Xie","year":"2018","journal-title":"Cancer Sci"},{"key":"2021122507442912700_R14","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.gene.2018.02.026","article-title":"Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRbeta and FGFR1","volume":"654","author":"Lin","year":"2018","journal-title":"Gene"},{"key":"2021122507442912700_R15","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13045-016-0332-8","article-title":"Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors","volume":"9","author":"Sun","year":"2016","journal-title":"J Hematol Oncol"},{"key":"2021122507442912700_R16","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/bjc.2017.478","article-title":"Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: A multicentre, randomised phase II trial (ALTER0302)","volume":"118","author":"Han","year":"2018","journal-title":"Br J Cancer"},{"key":"2021122507442912700_R17","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.1158\/1078-0432.CCR-17-3766","article-title":"Safety and efficacy of anlotinib, a multikinase angiogenesis inhibitor, in patients with refractory metastatic soft tissue sarcoma","volume":"24","author":"Chi","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2021122507442912700_R18","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1089\/thy.2018.0022","article-title":"Anlotinib for the treatment of patients with locally advanced or metastatic medullary thyroid cancer","volume":"28","author":"Sun","year":"2018","journal-title":"Thyroid"},{"key":"2021122507442912700_R19","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"2021122507442912700_R20","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N Engl J Med"},{"key":"2021122507442912700_R21","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1080\/0284186X.2016.1265666","article-title":"Assessment of ethnic differences in sunitinib outcome between Caucasian and Asian patients with metastatic renal cell carcinoma: A meta-analysis","volume":"56","author":"Liu","year":"2017","journal-title":"Acta Oncol"},{"key":"2021122507442912700_R22","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/jjco\/hyv045","article-title":"Real-world use of sunitinib in Japanese patients with advanced renal cell carcinoma: Efficacy, safety and biomarker analyses in 1689 consecutive patients","volume":"45","author":"Akaza","year":"2015","journal-title":"Jpn J Clin Oncol"},{"key":"2021122507442912700_R23","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/ajco.12163","article-title":"Sunitinib in metastatic renal cell carcinoma: An ethnic Asian subpopulation analysis for safety and efficacy","volume":"10","author":"Lee","year":"2014","journal-title":"Asia Pac J Clin Oncol"},{"key":"2021122507442912700_R24","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1200\/JCO.2013.50.8267","article-title":"Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study","volume":"32","author":"Escudier","year":"2014","journal-title":"J Clin Oncol"},{"key":"2021122507442912700_R25","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1200\/JCO.2016.70.7398","article-title":"Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: The Alliance A031203 CABOSUN Trial","volume":"35","author":"Choueiri","year":"2017","journal-title":"J Clin Oncol"},{"key":"2021122507442912700_R26","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2018-0839","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2018-0839","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/8\/e702\/41922687\/oncolo_24_8_e702.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/8\/e702\/41922687\/oncolo_24_8_e702.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T07:45:25Z","timestamp":1640418325000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/24\/8\/e702\/6439320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,22]]},"references-count":26,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,3,22]]},"published-print":{"date-parts":[[2019,8,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2018-0839","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,8,1]]},"published":{"date-parts":[[2019,3,22]]}}}